1 unchanged sentence
Our common stock is listed and traded under the ticker symbol “PCRX” on the Nasdaq Global Select Market.
−Removed: As of February 28, 2024, we had 11 holders of record of our common stock.
+Added: As of February 26, 2025, we had nine holders of record of our common stock.
The number of record holders is based on the actual number of holders registered on the books of our transfer agent and does not reflect the substantially greater amount of holders of shares in “street name,” whose shares are held of record by banks, brokers and other financial institutions.
Performance Graph
−Removed: The following graph shows the value of an investment of $100.00 made on December 31, 2018—the last trading day of 2018—in each of Pacira BioSciences, Inc.
+Added: The following graph and table shows the value of an investment of $100.00 made on December 31, 2019—the last trading day of 2019—in each of Pacira BioSciences, Inc.
(PCRX), the Nasdaq Composite Index (^IXIC), the Nasdaq Biotechnology Index (^NBI) and the S&P Pharmaceuticals Select Index (^SPSIPH).
2 unchanged sentences
The historical stock price performance of our common stock and the indices shown in this performance graph is not necessarily indicative of future stock price performance.
−Removed: Comparison of Five-Year Cumulative Total Returns
−Removed: Among Pacira BioSciences, Inc., the Nasdaq Composite Index,
+Added: Comparison of Five-Year Cumulative Total Returns Among
+Added: Pacira BioSciences, Inc., the Nasdaq Composite Index,
the Nasdaq Biotechnology Index and the S&P Pharmaceuticals Select Index
6 unchanged sentences
S&P Pharmaceuticals Select Index (^SPSIPH) $ 100.00 $ 113.59 $ 100.83 $ 89.53 $ 90.76 $ 93.69
+Added: Pacira BioSciences, Inc.
+Added: | 2024 Annual Report on Form 10-K | Page 73
Dividend Policy
We have never declared or paid any dividends on our common stock.
−Removed: We currently intend to retain any future earnings to finance the future development and expansion of our business, and as such we do not expect to pay any cash dividends on our common stock in the foreseeable future.
−Removed: The payment of future dividends, if any, will be at the discretion of our board of directors and will depend on our financial condition, results of operations, capital requirements, restrictions contained in the agreements governing our indebtedness, provisions of applicable law and any other factors our board of directors deems relevant.
−Removed: Pacira BioSciences, Inc.
−Removed: | 2023 Form 10-K | Page 72
−Removed: Table of Content s
+Added: We currently intend to retain any future earnings to finance the future development and expansion of our business, and as such we do not expect to pay any dividends on our common stock in the foreseeable future.
+Added: The payment of any future dividends would be at the discretion of our board of directors and will depend on our financial condition, results of operations, capital requirements, restrictions contained in the agreements governing our indebtedness, provisions of applicable law and any other factors our board of directors deems relevant.
+Added: Purchases of Equity Securities by the Registrant
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.